1. Innes EA. A brief history and overview of Toxoplasma gondii. Zoonoses Public Health. 2010;57(1):1-7.
2. Elsheikha HM, Marra CM, Zhu XQ. Epidemiology, pathophysiology, diagnosis, and management of cerebral toxoplasmosis. Clin Microbiol Rev. 2020;34(1): e00115-19.
3. Biesiada G, Kalinowska-Nowak A, Czepiel J, Mach T. Toxoplasmosis--epidemiology, clinical manifestation and infection in pregnant women. Przegl Lek. 2006;63(2):97-9.
4. Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis. 2012;44(11):805-14.
5. Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018;31(4): e00057-17.
6. Montazeri M, Mehrzadi S, Sharif M, et al. Drug resistance in Toxoplasma gondii. Front Microbiol. 2018;9:2587.
7. Cheraghipour K, Masoori L, Ezzatkhah F, et al. Effect of chitosan on Toxoplasma gondii infection: A systematic review. Parasite Epidemiol Control. 2020;11:e00189.
8. Ezhilarasi PN, Karthik P, Chhanwal N, Anandharamakrishnan C. Nanoencapsulat-ion techniques for food bioactive components: a review. Food Biop Technol. 2013;6:628-47.
9. Jafari SM. An overview of nanoencapsula-tion techniques and their classification. Nanoencapsul Tech Food Nutrac Industr. 2017:1-34.
10. Aranaz I, Alcántara AR, Civera MC, Arias C, Elorza B, Heras Caballero A, Acosta N. Chitosan: An overview of its properties and applications. Polymers (Basel). 2021;13(19):3256.
11. Escobar A, Perez M, Romanelli G, Blustein G. Thymol bioactivity: A review focusing on practical applications. Arabian J Chem. 2020;13(12):9243-69.
12. Parsaei P, Bahmani M, Naghdi N, Asadi-Samani M, Rafieian-Kopaei M. A review of therapeutic and pharmacological effects of thymol. Der Pharm Lett. 2016;8(2):150-4.
13. Wang X, Hu Y, Zhang Z, Zhang B. The application of thymol-loaded chitosan nanoparticles to control the biodeterioration of cultural heritage sites. Journal of Cultural Heritage. 2022;53:206-11.
14. Mahmoudvand H, Tavakoli Kareshk A, Nabi Moradi M, et al. Efficacy and safety of Zataria multiflora Boiss essential oil against acute toxoplasmosis in mice. Iran J Parasitol. 2020;15(1):22-30.
15. Shakibaie M, Ezzatkhah F, Gabal E, et al. Prophylactic effects of biogenic selenium nanoparticles on acute toxoplasmosis: an in vivo study. Ann Med Surg (Lond). 2020;54:85-88.
16. Baghdadi HB, Albalawi AE, Shater AF, et al. Linalool‐zinc oxide nanocomposite controls Toxoplasma gondii infection through inhibiting inflammation, oxidative stress, and pathogenicity. J Basic Microbiol. 2024; 64(8):e2400039.
17. Mahmoudvand H, Tavakoli Oliaei R, Mirbadie SR, et al. Efficacy and safety of Bunium persicum (Boiss) to inactivate protoscoleces during hydatid cyst operations. Surg Infect (Lurchmt). 2016;17(6):713-9.
18. Xu J, Song M, Fang Z, Zheng L, Huang X, Liu K. Applications and challenges of ultra-small particle size nanoparticles in tumor therapy. J Control Release. 2023;353:699-712.
19. Dolai J, Mandal K, Jana NR. Nanoparticle size effects in biomedical applications. ACS Appl Nano Material. 2021;4(7):6471-96.
20. Engstrom AM, Faase RA, Marquart GW, et al. Size-dependent interactions of lipid-coated gold nanoparticles: developing a better mechanistic understanding through model cell membranes and in vivo toxicity. Int J Nanomedicine. 2020; 15:4091-4104.
21. Teimouri A, Azami SJ, Keshavarz H, et al. Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain. Int J Nanomedicine. 2018; 13:1341-51.
22. Etewa SE, El-Maaty DA, Hamza RS, et al. Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice. J Parasit Dis. 2018;42:102-113.
23. Norouzi M, Mamaghani AJ, Tabaei SJ, et al. Evaluation of the efficacy of chitosan nanoparticles based on rosuvastatin in the treatment of acute toxoplasmosis: an in vitro and in vivo study. Microb Pathog. 2024; 195:106897.
24. Oliveira CB, Meurer YS, Medeiros TL, et al. Anti-Toxoplasma activity of estragole and thymol in murine models of congenital and noncongenital toxoplasmosis. J Parasitol. 2016;102(3):369-76.
25. Jain K, Jain NK. Novel therapeutic strategies for treatment of visceral leishmaniasis. Drug Discov Today. 2013;18(23-24):1272-81.
26. Mota ML, Lobo LT, Costa JM, et al. In vitro and in vivo antimalarial activity of essential oils and chemical components from three medicinal plants found in northeastern Brazil. Planta Med. 2012;78(7):658-64.
27. Fujisaki R, Kamei K, Yamamura M, et al. In vitro and in vivo anti-plasmodial activity of essential oils, including hinokitiol. Southeast Asian J Trop Med Public Health. 2012;43(2):270-9.
28. Tanghort M, Chefchaou H, Mzabi A, et al. Oocysticidal effect of essential oils and their major components on Cryptosporidium baileyi and Cryptosporidium galli. Inter J Poultry Sci, 2019;18: 475-482.
29. Marchese A, Orhan IE, Daglia M, et al. Antibacterial and antifungal activities of thymol: A brief review of the literature. Food Chem. 2016;210:402-14.
30. Memar MY, Raei P, Alizadeh N, et al. Carvacrol and thymol: strong antimicrobial agents against resistant isolates. Rev Med Microbiol. 2017;28(2):63-8.
31. van de Crommenacker J, Richardson DS, Koltz AM, Hutchings K, Komdeur J. Parasitic infection and oxidative status are associated and vary with breeding activity in the Seychelles warbler. Proc Biol Sci. 2012;279(1733):1466-76.
32. Szewczyk-Golec K, Pawłowska M, Wesołowski R, et al. Oxidative stress as a possible target in the treatment of toxoplasmosis: perspectives and ambiguities. Int J Mol Sci. 2021;22(11):5705.
33. De Titto EH, Catterall JR, Remington JS. Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi. J Immunol. 1986; 137(4): 1342–1345
34. Chang HR, Grau GE, Pechere JC. Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology. 1990; 69(1): 33–37.
35. Fielden MR, Kolaja KL. The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin Drug Saf. 2008;7(2):107-10.